Intelligent Bio Solutions Partners with PREMIUM for Manufacturing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: Yahoo Finance
- Partnership Announcement: Intelligent Bio Solutions has entered into a manufacturing partnership with PREMIUM, aimed at enhancing production capabilities and market responsiveness, thereby expanding its influence in the biotechnology sector.
- Market Potential: This collaboration will enable Intelligent Bio Solutions to leverage PREMIUM's advanced manufacturing technologies, which is expected to significantly improve product quality and production efficiency, strengthening its position in a competitive market.
- Strategic Implications: By partnering with PREMIUM, Intelligent Bio Solutions can not only optimize its supply chain management but also accelerate time-to-market for new products, addressing the growing market demand effectively.
- Future Outlook: The establishment of this partnership signifies Intelligent Bio Solutions' ongoing expansion in the biotechnology industry, which is anticipated to generate new revenue streams and long-term growth opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INBS
About INBS
Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intelligent Bio Solutions to Participate in Planet MicroCap Conference
- Conference Participation: Intelligent Bio Solutions Inc. will participate in the Planet MicroCap Conference from June 16-18, 2026, at the Bellagio Hotel in Las Vegas, showcasing its innovative non-invasive testing solutions, which is expected to attract potential investor interest.
- Presentation Schedule: The management team is set to present on June 17 from 8:00 to 8:30 AM, aiming to highlight the advantages of its Intelligent Fingerprinting Drug Screening System, thereby enhancing market awareness and attracting investments.
- One-on-One Meetings: Throughout the event, INBS will arrange one-on-one meetings with investors, providing opportunities for in-depth business discussions, which aim to strengthen relationships with potential investors and drive future funding opportunities.
- Technological Advantage: The Intelligent Fingerprinting Drug Screening System enables rapid and hygienic drug testing through fingerprint sweat analysis, delivering results in under ten minutes, which is expected to provide a crucial tool for employers in safety-critical industries, enhancing industry safety standards.
See More
Initiation of Intelligent Fingerprinting Drug Screening System Study
- Study Launch: Intelligent Bio Solutions Inc. has announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission, expecting to complete participant enrollment and data collection by the end of July 2026, aimed at validating the accuracy of the Intelligent Fingerprinting Drug Screening System.
- Participant Recruitment: The study will enroll 135 donor participants randomized into dosing groups, with demographics designed to reflect the diversity of the U.S. population, ensuring the broad applicability and effectiveness of the study results.
- User Performance Evaluation: The study will assess key performance metrics including the system's sensitivity, specificity, and overall accuracy, with results independently confirmed via liquid chromatography-tandem mass spectrometry (LC-MS/MS), ensuring the reliability and validity of the data.
- Market Competitive Advantage: The CEO stated that demonstrating typical workplace personnel can accurately operate the system will validate a core competitive advantage, enhancing its market position in workplace drug screening, particularly in the potential for U.S. market expansion.
See More
Intelligent Bio Solutions Reports Q3 Financial Results
- Financial Highlights: Intelligent Bio Solutions reported a Q3 GAAP EPS of -$1.80, indicating a loss; however, the company showed resilience with improvements in revenue and gross margin.
- Revenue Growth: The Q3 revenue reached $1.06 million with a gross profit margin of 50.5%, up from 46.8% in the same period last year, reflecting positive progress in cost management and sales strategies.
- Sales Performance: For the nine months ended March 31, 2026, cartridge sales totaled $1.86 million, a 46% year-over-year increase, representing 61% of total revenue, indicating strong product demand.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $6.86 million, significantly up from $740,371 at December 31, 2025, enhancing financial stability and future investment capacity.
See More
Intelligent Bio Solutions Reports Strong Q3 Revenue Growth and Margin Expansion
- Significant Revenue Growth: Q3 cartridge revenue surged 59% year-over-year to $703,538, representing 66% of total quarterly sales, indicating strong performance under the recurring revenue model and expected to drive future market expansion.
- Robust Nine-Month Performance: Total revenue for the nine months ended March 31, 2026, reached $3.07 million, up 39% year-over-year, building on a $2.01 million first-half milestone, demonstrating sustained commercial momentum.
- Margin Expansion: The gross margin for Q3 hit 50.5%, up approximately 800 basis points from 46.8% in the prior year, reflecting successful operational efficiencies and increased sales volumes, enhancing unit economics.
- Market Investment Returns: The company's $1.77 million marketing investment over the past nine months directly contributed to 39% revenue growth, while Q3 marketing spend decreased by 42% year-over-year, indicating improved brand awareness and market presence.
See More
Intelligent Bio Solutions Launches Rapid Drug Testing Validation Study
- Significant Market Potential: The U.S. roadside drug testing market is projected to reach $1.62 billion by 2030, growing at a CAGR of 4.71%, providing INBS with substantial market opportunities amid rising drug-related accidents and fatalities.
- Analysis Time Reduction: The validation study aims to cut the analysis time of INBS's drug screening system from ten minutes to under three minutes, significantly enhancing law enforcement efficiency and improving road safety.
- Clear Technological Advantage: By providing rapid results, INBS's system not only meets the urgent needs of law enforcement for quick testing but also strengthens its market position as states expand drug testing programs following marijuana legalization.
- Diversified Market Expansion: Accelerated testing times will enable INBS to penetrate additional high-value sectors, such as drug treatment and consumer health markets, further enhancing its competitiveness in the global drug screening products market.
See More
Intelligent Bio Solutions Completes Penetration Testing for FDA Submission
- Successful Penetration Testing: Intelligent Bio Solutions Inc. has successfully completed penetration testing, identifying no major security vulnerabilities, which validates the robustness of its existing security infrastructure and strengthens its upcoming FDA 510(k) submission compliance.
- Security Upgrades Implemented: The company has implemented additional security upgrades in its drug testing technology, including enhanced encrypted identification tags and improved firmware safeguards, ensuring test integrity and protecting against cyber threats, thereby enhancing its commitment to data protection.
- Market Opportunity Expansion: By addressing security requirements early in the FDA 510(k) submission process, INBS positions its technology to meet evolving FDA guidance on medical device cybersecurity, and obtaining FDA clearance could open new revenue and expansion opportunities in the multi-billion-dollar U.S. drug screening market.
- Innovation Potential: INBS's Intelligent Fingerprinting Drug Screening System aims to revolutionize portable testing through fingerprint sweat analysis, providing results in under ten minutes, which is expected to become a valuable tool for employers in safety-critical industries, further driving the company's growth in global markets.
See More
Intelligent Bio Solutions to Participate in Planet MicroCap Conference
- Conference Participation: Intelligent Bio Solutions Inc. will participate in the Planet MicroCap Conference from June 16-18, 2026, at the Bellagio Hotel in Las Vegas, showcasing its innovative non-invasive testing solutions, which is expected to attract potential investor interest.
- Presentation Schedule: The management team is set to present on June 17 from 8:00 to 8:30 AM, aiming to highlight the advantages of its Intelligent Fingerprinting Drug Screening System, thereby enhancing market awareness and attracting investments.
- One-on-One Meetings: Throughout the event, INBS will arrange one-on-one meetings with investors, providing opportunities for in-depth business discussions, which aim to strengthen relationships with potential investors and drive future funding opportunities.
- Technological Advantage: The Intelligent Fingerprinting Drug Screening System enables rapid and hygienic drug testing through fingerprint sweat analysis, delivering results in under ten minutes, which is expected to provide a crucial tool for employers in safety-critical industries, enhancing industry safety standards.
See More
Initiation of Intelligent Fingerprinting Drug Screening System Study
- Study Launch: Intelligent Bio Solutions Inc. has announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission, expecting to complete participant enrollment and data collection by the end of July 2026, aimed at validating the accuracy of the Intelligent Fingerprinting Drug Screening System.
- Participant Recruitment: The study will enroll 135 donor participants randomized into dosing groups, with demographics designed to reflect the diversity of the U.S. population, ensuring the broad applicability and effectiveness of the study results.
- User Performance Evaluation: The study will assess key performance metrics including the system's sensitivity, specificity, and overall accuracy, with results independently confirmed via liquid chromatography-tandem mass spectrometry (LC-MS/MS), ensuring the reliability and validity of the data.
- Market Competitive Advantage: The CEO stated that demonstrating typical workplace personnel can accurately operate the system will validate a core competitive advantage, enhancing its market position in workplace drug screening, particularly in the potential for U.S. market expansion.
See More
Intelligent Bio Solutions Reports Q3 Financial Results
- Financial Highlights: Intelligent Bio Solutions reported a Q3 GAAP EPS of -$1.80, indicating a loss; however, the company showed resilience with improvements in revenue and gross margin.
- Revenue Growth: The Q3 revenue reached $1.06 million with a gross profit margin of 50.5%, up from 46.8% in the same period last year, reflecting positive progress in cost management and sales strategies.
- Sales Performance: For the nine months ended March 31, 2026, cartridge sales totaled $1.86 million, a 46% year-over-year increase, representing 61% of total revenue, indicating strong product demand.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $6.86 million, significantly up from $740,371 at December 31, 2025, enhancing financial stability and future investment capacity.
See More
Intelligent Bio Solutions Reports Strong Q3 Revenue Growth and Margin Expansion
- Significant Revenue Growth: Q3 cartridge revenue surged 59% year-over-year to $703,538, representing 66% of total quarterly sales, indicating strong performance under the recurring revenue model and expected to drive future market expansion.
- Robust Nine-Month Performance: Total revenue for the nine months ended March 31, 2026, reached $3.07 million, up 39% year-over-year, building on a $2.01 million first-half milestone, demonstrating sustained commercial momentum.
- Margin Expansion: The gross margin for Q3 hit 50.5%, up approximately 800 basis points from 46.8% in the prior year, reflecting successful operational efficiencies and increased sales volumes, enhancing unit economics.
- Market Investment Returns: The company's $1.77 million marketing investment over the past nine months directly contributed to 39% revenue growth, while Q3 marketing spend decreased by 42% year-over-year, indicating improved brand awareness and market presence.
See More
Intelligent Bio Solutions Launches Rapid Drug Testing Validation Study
- Significant Market Potential: The U.S. roadside drug testing market is projected to reach $1.62 billion by 2030, growing at a CAGR of 4.71%, providing INBS with substantial market opportunities amid rising drug-related accidents and fatalities.
- Analysis Time Reduction: The validation study aims to cut the analysis time of INBS's drug screening system from ten minutes to under three minutes, significantly enhancing law enforcement efficiency and improving road safety.
- Clear Technological Advantage: By providing rapid results, INBS's system not only meets the urgent needs of law enforcement for quick testing but also strengthens its market position as states expand drug testing programs following marijuana legalization.
- Diversified Market Expansion: Accelerated testing times will enable INBS to penetrate additional high-value sectors, such as drug treatment and consumer health markets, further enhancing its competitiveness in the global drug screening products market.
See More
Intelligent Bio Solutions Completes Penetration Testing for FDA Submission
- Successful Penetration Testing: Intelligent Bio Solutions Inc. has successfully completed penetration testing, identifying no major security vulnerabilities, which validates the robustness of its existing security infrastructure and strengthens its upcoming FDA 510(k) submission compliance.
- Security Upgrades Implemented: The company has implemented additional security upgrades in its drug testing technology, including enhanced encrypted identification tags and improved firmware safeguards, ensuring test integrity and protecting against cyber threats, thereby enhancing its commitment to data protection.
- Market Opportunity Expansion: By addressing security requirements early in the FDA 510(k) submission process, INBS positions its technology to meet evolving FDA guidance on medical device cybersecurity, and obtaining FDA clearance could open new revenue and expansion opportunities in the multi-billion-dollar U.S. drug screening market.
- Innovation Potential: INBS's Intelligent Fingerprinting Drug Screening System aims to revolutionize portable testing through fingerprint sweat analysis, providing results in under ten minutes, which is expected to become a valuable tool for employers in safety-critical industries, further driving the company's growth in global markets.
See More
